Trial Profile
Evaluation for effect of SGLT2 inhibitor on postprandial hyperglycemia and cardiac function in diabetic patients with coronary artery disease
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 11 Mar 2022
Price :
$35
*
At a glance
- Drugs Tofogliflozin (Primary)
- Indications Coronary artery disease; Diabetes mellitus
- Focus Therapeutic Use
- 05 Mar 2022 Status changed from recruiting to discontinued.
- 06 Mar 2018 New trial record